JD Health's operating profit in the first quarter increased significantly by 70.4% to 1.825 billion yuan.

JD HEALTH (06618) released its performance for the first quarter of 2026. The group achieved revenue of 19.468 billion yuan (RMB) for the three months ending March 31, 2026, representing a year-on-year growth of 17%. Operating profit was 1.825 billion yuan, an increase of 70.4% compared to the previous year. In the first quarter of 2026, JD HEALTH reached strategic cooperation agreements with several well-known pharmaceutical enterprises including Oucologne, Kefu, China Resources Jiangzhong Pharmaceutical, and Shou'er Pharmaceuticals. With Oucologne, they are collaborating in areas such as cardiovascular, respiratory, and women's health to promote the application of AI-assisted diagnosis and digital disease management. JD HEALTH also maintained its core advantage of being the "first platform for new drug releases on the entire network", launching over 30 new drugs in the first quarter, including Roche's global first oral targeted drug for the treatment of chronic spontaneous urticaria, Rivipto, and the first domestically approved innovative drug for the treatment of vitiligo, Balutow. In the first quarter of 2026, AI Jingyi integrated "medical, examination, diagnosis, and medication" into a closed-loop service. For users seeking health advice, the platform not only provides professional recommendations but also directly connects to online consultations, at-home rapid tests, home nursing services, and drug delivery from JD Pharmacy, forming a comprehensive and complete service loop. The number of users using the AI doctor "Dawei" in the first three months of 2026 has already exceeded the total for the entire year of 2025.